Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) EPS (Weighted Average and Diluted) (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of EPS (Weighted Average and Diluted) data on record, last reported at $6.27 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 3816.02% year-over-year to $6.27; the TTM value through Dec 2025 reached $6.27, up 12431.25%, while the annual FY2025 figure was $1.64, 3181.25% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $6.27 in Q4 2025 per INDV's latest filing, up from $0.33 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $6.27 in Q4 2025 and bottomed at -$0.72 in Q2 2024.